AI assistant
FATE THERAPEUTICS INC — Director's Dealing 2014
Apr 3, 2014
34091_dirs_2014-04-03_58cb0ad8-ca7f-443e-b16f-3071c6927a37.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: FATE THERAPEUTICS INC (FATE)
CIK: 0001434316
Period of Report: 2014-04-01
Reporting Person: Weyer Christian (Director, See remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-04-01 | Common Stock | M | 7738 | $1.37 | Acquired | 7738 | Direct |
| 2014-04-01 | Common Stock | S | 7738 | $9.019 | Disposed | 0 | Direct |
| 2014-04-02 | Common Stock | M | 2262 | $1.37 | Acquired | 2262 | Direct |
| 2014-04-02 | Common Stock | S | 2262 | $9.0164 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-04-01 | Stock Option (right to buy) | $1.37 | M | 7738 | Disposed | 2022-10-09 | Common Stock (7738) | Direct |
| 2014-04-02 | Stock Option (right to buy) | $1.37 | M | 2262 | Disposed | 2022-10-09 | Common Stock (2262) | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2013.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.90 to $9.50, inclusive
F3: The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.8497 to $9.105, inclusive.
F5: The shares subject to this option shall vest and become exercisable at the rate of 1/4th of the shares on October 8, 2013 and 1/48th of the shares each month thereafter such that this option is fully exercisable on October 8, 2016. This option is subject to accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer.
F6: Not applicable.